orforglipron vs Semaglutide (Rybelsus)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT06050577 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | orforglipron | Semaglutide (Rybelsus) |
|---|---|---|
| HbA1c, change | -1.4% vs -0.1%−1.3 vs placeboNCT0597194014 other results
| -1.6% vs -0.2%−1.4 vs placeboNCT0410954734 other results
|
| Body weight, change (kg) | -7.3 vs -1.3−6 vs placeboNCT059719407 other results
| -4.2 vs -1.3−2.9 vs placeboNCT0391432639 other results
|
| HbA1c below 7% | 79.0% vs 37.1%+41.9 vs placeboNCT059719407 other results
| —Not posted · NCT07271251 |
| Fasting plasma glucose, change | -2.0 vs -1.1−0.9 vs placeboNCT044264744 other results
| -1.9 vs -0.7−1.2 vs placeboNCT0286341939 other results
|
| 3-point MACE (% with event) | —Not posted · NCT05803421 | 12% vs 13.8%−1.8 vs placeboNCT039143261 other result
|
HbA1c, change
- orforglipron
- -1.4% vs -0.1%−1.3 vs placeboNCT05971940
14 other results
- -1.6% vs -0.1% NCT05971940
- -1.3% vs -0.1% NCT05971940
- -2.0% vs -0.4% NCT05048719
- -1.9% vs -0.4% NCT05048719
- -1.2% vs -0.4% NCT05048719
- -2.1% vs -0.4% NCT05048719
- -1.8% vs -0.4% NCT05048719
- -2.0% vs -1.1% NCT05048719
- -1.9% vs -1.1% NCT05048719
- -1.2% vs -1.1% NCT05048719
- -2.1% vs -1.1% NCT05048719
- -1.8% vs -1.1% NCT05048719
- -1.7% vs -0.5% NCT05872620
- 1.7% vs 0.8% NCT06192108
- Semaglutide (Rybelsus)
- -1.6% vs -0.2%−1.4 vs placeboNCT04109547
34 other results
- -1.5% vs -0.2% NCT04109547
- -1.1% vs -0.2% NCT04109547
- -0.7% vs -0.1% NCT03914326
- -1% vs -0.3% NCT02692716
- -1.2% vs -0.1% NCT02863419
- -1.2% vs -0.2% NCT03021187
- -0.9% vs -0.2% NCT03021187
- -0.6% vs -0.2% NCT03021187
- -1.5% vs 0.1% NCT03018028
- -1.4% vs 0.1% NCT03018028
- -1% vs 0.1% NCT03018028
- -2% vs -1.6% NCT03015220
- -1.3% vs -0.9% NCT02863328
- -1.2% vs -0.7% NCT02607865
- -1.1% vs -0.7% NCT02607865
- -1% vs -0.7% NCT02607865
- -0.9% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -1.8% vs -1.4% NCT03015220
- -1.7% vs -1.6% NCT03015220
- -1.4% vs -1.4% NCT03015220
- -1.1% vs -1.6% NCT03015220
- -0.8% vs -1.4% NCT03015220
- -1.3% vs -0.8% NCT02849080
- -0.2% vs 0% NCT02849080
- -2.0% vs -0.4% NCT01923181
- -1.8% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.7% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.2% vs -0.4% NCT01923181
- -0.9% vs -0.4% NCT01923181
- -1.2% vs -1.0% NCT05035082
Body weight, change (kg)
- orforglipron
- -7.3 vs -1.3−6 vs placeboNCT05971940
7 other results
- -5.5 vs -1.3 NCT05971940
- -4.4 vs -1.3 NCT05971940
- -9.5 vs -2.2 NCT05048719
- -6.5 vs -2.2 NCT05048719
- -3.7 vs -2.2 NCT05048719
- -10.1 vs -2.2 NCT05048719
- -9.7 vs -2.2 NCT05048719
- Semaglutide (Rybelsus)
- -4.2 vs -1.3−2.9 vs placeboNCT03914326
39 other results
- -4.2 vs -0.8 NCT02692716
- -3.1 vs -1.1 NCT04109547
- -4.4 vs -1 NCT02863419
- -3.8 vs 0.5 NCT03021187
- -2.4 vs -1.1 NCT03018028
- -2.9 vs -1 NCT03018028
- -2.2 vs -1.1 NCT04109547
- -2.2 vs 0.5 NCT03021187
- -1.1 vs -1.1 NCT04109547
- -0.9 vs 0.5 NCT03021187
- -1.2 vs -1.1 NCT03018028
- -0.8 vs -1 NCT03018028
- -0.4 vs -1.1 NCT03018028
- 0 vs -1 NCT03018028
- -3.8 vs -0.5 NCT04017832
- -4 vs -3.7 NCT02863328
- -3.5 vs -0.7 NCT02607865
- -3.2 vs -1 NCT02607865
- -2.9 vs -0.5 NCT04017832
- -2.5 vs -0.7 NCT02607865
- -2.8 vs -1 NCT02607865
- -2.2 vs 0.3 NCT03015220
- -1.7 vs 1 NCT03015220
- -0.9 vs 1 NCT03015220
- -1.4 vs -0.5 NCT04017832
- -1.6 vs -0.7 NCT02607865
- -1.8 vs -1 NCT02607865
- -1 vs 0.3 NCT03015220
- -0.1 vs 0.3 NCT03015220
- 0 vs 1 NCT03015220
- -2.6 vs -0.9 NCT02849080
- -6.9 vs -1.2 NCT01923181
- -5.9 vs -1.2 NCT01923181
- -8.3 vs -1.2 NCT01923181
- -5.8 vs -1.2 NCT01923181
- -4.9 vs -1.2 NCT01923181
- -2.9 vs -1.2 NCT01923181
- -2.0 vs -1.2 NCT01923181
- -3.9 vs -3.5 NCT05035082
HbA1c below 7%
- orforglipron
- 79.0% vs 37.1%+41.9 vs placeboNCT05971940
7 other results
- 81.3% vs 37.1% NCT05971940
- 78.2% vs 37.1% NCT05971940
- 92.8% vs 24.3% NCT05048719
- 78.9% vs 24.3% NCT05048719
- 65.2% vs 24.3% NCT05048719
- 95.8% vs 24.3% NCT05048719
- 91.2% vs 24.3% NCT05048719
- Semaglutide (Rybelsus)
- —Not posted · NCT07271251
Fasting plasma glucose, change
- orforglipron
- -2.0 vs -1.1−0.9 vs placeboNCT04426474
4 other results
- -3 vs -1.1 NCT04426474
- -2.9 vs -1.1 NCT04426474
- -2.4 vs -1.1 NCT04426474
- -2.3 vs -1.1 NCT04426474
- Semaglutide (Rybelsus)
- -1.9 vs -0.7−1.2 vs placeboNCT02863419
39 other results
- -1.6 vs -0.1 NCT03021187
- -1.9 vs -0.2 NCT02906930
- -2.0 vs -0.3 NCT02863419
- -1.6 vs -0.3 NCT02827708
- -1.4 vs 0.5 NCT03021187
- -1.1 vs -0.1 NCT03021187
- -1.5 vs -0.2 NCT02906930
- -1.1 vs 0.5 NCT03021187
- -0.8 vs -0.1 NCT03021187
- -0.9 vs -0.2 NCT02906930
- -0.5 vs 0.5 NCT03021187
- -2.3 vs 0.3 NCT03018028
- -2.4 vs -0.4 NCT03018028
- -1.6 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.1 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.6 vs -0.9 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.8 vs -1.0 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.7 vs -0.9 NCT02607865
- -2 vs -0.5 NCT04017832
- -1.1 vs -0.9 NCT02607865
- -1.3 vs -1.0 NCT02607865
- -1.2 vs -0.9 NCT02607865
- -2.7 vs -2.2 NCT03015220
- -1.8 vs -0.5 NCT04017832
- -1.1 vs -0.9 NCT02607865
- -1.0 vs -1.0 NCT02607865
- -0.8 vs -0.9 NCT02607865
- -2.2 vs -1.8 NCT03015220
- -2.0 vs -1.8 NCT03015220
- -2.3 vs -2.2 NCT03015220
- -0.9 vs -1.8 NCT03015220
- -1.0 vs -0.5 NCT04017832
- -1.2 vs -2.2 NCT03015220
- -0.3 vs 0.0 NCT02849080
- -2.4 vs -1.4 NCT02849080
3-point MACE (% with event)
- orforglipron
- —Not posted · NCT05803421
- Semaglutide (Rybelsus)
- 12% vs 13.8%−1.8 vs placeboNCT03914326
1 other result
- 3.8% vs 4.8% NCT02692716
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. orforglipron: 14 of 14 rows · Semaglutide (Rybelsus): 13 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | orforglipron Rows use multiple source trials | Semaglutide (Rybelsus) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg No placebo or comparator arm | -2.5 kg @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-1.9 kg @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -0.7 kg @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -1.6 kg @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses-2.9 kg @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -2.5 kg @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.13% (n=125) @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-1.97% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -1.71% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -1.5% (n=497) @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 5 more doses-0.4% (n=333) @ 52wk14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -2.1% (n=492) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -1% (n=339) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -1.9% (n=475) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -0.8% (n=345) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 90.82% (n=125) @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses86.11% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 82.73% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 39% (n=536) @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses63% (n=535) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 50.5% (n=535) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants No placebo or comparator arm | 84.56% (n=125) @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses76.23% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 62.64% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 25.8% (n=536) @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses51.2% (n=535) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 39.6% (n=535) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -6 vs -0.5 placebo mmHg @ 40wk36 mga,b,c,d NCT05971940 · Phase 3 · registry result, not featured evidence show 2 more doses-6.1 vs -0.5 placebo mmHg @ 40wk12 mg NCT05971940 · Phase 3 · registry result, not featured evidence -3.2 vs -0.5 placebo mmHg @ 40wk3 mg NCT05971940 · Phase 3 · registry result, not featured evidence | -4 vs -2 placebo mmHg @ 26wk14 mga,b,c,d NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-2 vs -2 placebo mmHg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1 vs -2 placebo mmHg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| Waist Circumference Change absolute change · cm No placebo or comparator arm | -6.5 cm @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-4.6 cm @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -2.4 cm @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -4 cm @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses-6 cm @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -5 cm @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Weight percent change · % of baseline | -9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mge,c,f NCT05872620 · Phase 3 · sponsor-reported, not registry data | -3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wke,c,f NCT02849080 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -6.75 kg @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-5.08 kg @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -1.81 kg @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -4.4 kg @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses-8.3 kg @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -7.1 kg @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Weight Loss 10% responder rate · % of participants No placebo or comparator arm | 37.91% (n=125) @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses24.68% (n=127) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 10.11% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 13.9% (n=536) @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses37.2% (n=535) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 29% (n=535) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Weight Loss 5% responder rate · % of participants No placebo or comparator arm | 65.14% (n=125) @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses49.52% (n=127) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 27% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 41% (n=536) @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses67.5% (n=535) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 60% (n=535) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 6.7%36 mgg NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results5.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 5.3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3.5%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 8.8%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 6.3%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 7.4%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 11.8%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.7%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 7.8%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 9.4%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 57.1%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence | 6.9%14 mgg NCT02906930 · Phase 3 show 39 more results8%7 mg NCT02906930 · Phase 3 3.4%3 mg NCT02906930 · Phase 3 2.7%14 mg NCT02863328 · Phase 3 5.8%14 mg NCT02607865 · Phase 3 6.4%7 mg NCT02607865 · Phase 3 7.1%3 mg NCT02607865 · Phase 3 2.8%14 mg NCT02863419 · Phase 3 3.1%14 mg NCT02827708 · Phase 3 3.3%14 mg NCT03021187 · Phase 3 4.9%7 mg NCT03021187 · Phase 3 5.4%3 mg NCT03021187 · Phase 3 1.5% NCT03914326 · Phase 3 0.3% NCT02692716 · Phase 3 11.8% NCT05035082 · Phase 4 · registry result, not featured evidence 5.4%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 5.6%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.4%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 7.2%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 5%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.6%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 2.1%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 2.3%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.5%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 2.3%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 11.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 11.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 5.7%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 8.6%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.2%36 mgg NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results4.4%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.5%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.4%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0.7%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.6%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 35.7%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence | —14 mgg NCT02906930 · Phase 3 show 39 more results—7 mg NCT02906930 · Phase 3 —3 mg NCT02906930 · Phase 3 —14 mg NCT02863328 · Phase 3 —14 mg NCT02607865 · Phase 3 —7 mg NCT02607865 · Phase 3 —3 mg NCT02607865 · Phase 3 —14 mg NCT02863419 · Phase 3 —14 mg NCT02827708 · Phase 3 —14 mg NCT03021187 · Phase 3 —7 mg NCT03021187 · Phase 3 —3 mg NCT03021187 · Phase 3 — NCT03914326 · Phase 3 — NCT02692716 · Phase 3 — NCT05035082 · Phase 4 · registry result, not featured evidence —14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —14 mg NCT04017832 · Phase 3 · registry result, not featured evidence —7 mg NCT04017832 · Phase 3 · registry result, not featured evidence —3 mg NCT04017832 · Phase 3 · registry result, not featured evidence —14 mg NCT04109547 · Phase 3 · registry result, not featured evidence —7 mg NCT04109547 · Phase 3 · registry result, not featured evidence —3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence —14 mg NCT03018028 · Phase 3 · registry result, not featured evidence —7 mg NCT03018028 · Phase 3 · registry result, not featured evidence —3 mg NCT03018028 · Phase 3 · registry result, not featured evidence —14 mg NCT03015220 · Phase 3 · registry result, not featured evidence —7 mg NCT03015220 · Phase 3 · registry result, not featured evidence —3 mg NCT03015220 · Phase 3 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —20 mg NCT01923181 · Phase 2 · registry result, not featured evidence —10 mg NCT01923181 · Phase 2 · registry result, not featured evidence —5 mg NCT01923181 · Phase 2 · registry result, not featured evidence —2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.5%36 mgg NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results2.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 2.8%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.1%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.6%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2.9%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 1.8%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 5.9%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.1%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%3 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence | 1.1%14 mgg NCT02906930 · Phase 3 show 39 more results1.7%7 mg NCT02906930 · Phase 3 2.9%3 mg NCT02906930 · Phase 3 6.6%14 mg NCT02863328 · Phase 3 9.5%14 mg NCT02607865 · Phase 3 10.1%7 mg NCT02607865 · Phase 3 13.7%3 mg NCT02607865 · Phase 3 10.9%14 mg NCT02863419 · Phase 3 10.4%14 mg NCT02827708 · Phase 3 6.6%14 mg NCT03021187 · Phase 3 10.5%7 mg NCT03021187 · Phase 3 13.6%3 mg NCT03021187 · Phase 3 47.9% NCT03914326 · Phase 3 18.9% NCT02692716 · Phase 3 10.2% NCT05035082 · Phase 4 · registry result, not featured evidence 9.9%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.2%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 10.7%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 3%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.9%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 7.7%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 4.6%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 9.5%Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence 14.2%Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence 9%Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 0%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 4.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 5.4%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 3%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 6.9%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 0%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 1.4%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 36 mgg constipation 29.1% nausea 27.6% nasopharyngitis 16.4% NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results12 mg constipation 30.4% nasopharyngitis 22.2% nausea 19.3% NCT06010004 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 17.4% constipation 16.7% nausea 12.9% NCT06010004 · Phase 3 · registry result, not featured evidence 36 mg diarrhoea 25.5% (placebo 9.4%) diabetic retinopathy 17% (placebo 15.2%) nausea 17% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 12 mg diarrhoea 21.2% (placebo 9.4%) dyspepsia 21.2% (placebo 7.2%) nausea 19% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 3 mg diarrhoea 18.9% (placebo 9.4%) diabetic retinopathy 14.7% (placebo 15.2%) nausea 12.6% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 36 mg nausea 37% (placebo 5.5%) vomiting 33.3% (placebo 1.8%) diarrhoea 25.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 36 mg nausea 26.5% (placebo 5.5%) vomiting 20.6% (placebo 1.8%) eructation 8.8% (placebo 0%) NCT05048719 · Phase 2 · registry result, not featured evidence 12 mg nausea 37.5% (placebo 5.5%) vomiting 21.4% (placebo 1.8%) diarrhoea 16.1% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 23.5% (placebo 5.5%) diarrhoea 21.6% (placebo 7.3%) constipation 13.7% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg vomiting 35.5% (placebo 1.8%) diarrhoea 29% (placebo 7.3%) nausea 29% (placebo 5.5%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 28.1% (placebo 7.3%) nausea 25% (placebo 5.5%) vomiting 21.9% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 24 mg nausea 34% (placebo 5.5%) vomiting 27.7% (placebo 1.8%) diarrhoea 14.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 55.6% (placebo 25%) constipation 33.3% (placebo 0%) vomiting 22.2% (placebo 25%) NCT05086445 · Phase 1 · registry result, not featured evidence 2 mg vomiting 40% (placebo 25%) nausea 30% (placebo 25%) abdominal distension 20% (placebo 0%) NCT05086445 · Phase 1 · registry result, not featured evidence 3/6/12/15 mg QD nausea 50% (placebo 5.9%) vomiting 50% (placebo 0%) decreased appetite 40% (placebo 11.8%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21 mg QD nausea 42.9% (placebo 5.9%) decreased appetite 28.6% (placebo 11.8%) covid-19 21.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21/27 mg QD decreased appetite 55.6% (placebo 11.8%) vomiting 55.6% (placebo 0%) nausea 33.3% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9 mg QD vomiting 55.6% (placebo 0%) decreased appetite 44.4% (placebo 11.8%) nausea 44.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9/21/36/45 mg QD nausea 77.8% (placebo 5.9%) decreased appetite 66.7% (placebo 11.8%) vomiting 55.6% (placebo 0%) NCT04426474 · Phase 1 · registry result, not featured evidence | 14 mgg nausea 16% (placebo 5.6%) vomiting 6.9% (placebo 2.2%) decreased appetite 5.1% (placebo 0.6%) NCT02906930 · Phase 3 show 38 more results7 mg nasopharyngitis 6.3% (placebo 3.4%) headache 5.7% (placebo 5.1%) diarrhoea 5.1% (placebo 2.2%) NCT02906930 · Phase 3 3 mg diarrhoea 8.6% (placebo 2.2%) nausea 8% (placebo 5.6%) nasopharyngitis 5.7% (placebo 3.4%) NCT02906930 · Phase 3 14 mg nausea 19.3% (placebo 3.5%) diarrhoea 15.1% (placebo 7.7%) nasopharyngitis 14.4% (placebo 10.6%) NCT02863419 · Phase 3 14 mg nausea 19% (placebo 7.5%) constipation 11.7% (placebo 3.7%) vomiting 11.7% (placebo 1.2%) NCT02827708 · Phase 3 14 mg nausea 22.7% (placebo 7.1%) diarrhoea 14.4% (placebo 6%) decreased appetite 12.7% (placebo 1.1%) NCT03021187 · Phase 3 7 mg nausea 16.6% (placebo 7.1%) diarrhoea 12.2% (placebo 6%) nasopharyngitis 11.6% (placebo 14.7%) NCT03021187 · Phase 3 3 mg nasopharyngitis 14.7% (placebo 14.7%) nausea 11.4% (placebo 7.1%) diarrhoea 8.7% (placebo 6%) NCT03021187 · Phase 3 diabetic retinopathy 19.5% (placebo 19.3%) covid-19 15.7% (placebo 16.1%) nausea 7.1% (placebo 1.3%) NCT03914326 · Phase 3 14 mg once daily nausea 18% diarrhoea 12.4% covid-19 11.8% NCT04707469 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 27.3% vomiting 18.2% diarrhoea 14.2% NCT04707469 · Phase 3 · registry result, not featured evidence 25 mg once daily nausea 27.2% vomiting 17% diarrhoea 12.9% NCT04707469 · Phase 3 · registry result, not featured evidence 14 mg diarrhoea 13.3% nausea 12.2% decreased appetite 9.4% NCT04017832 · Phase 3 · registry result, not featured evidence 7 mg nausea 10.9% diarrhoea 8.9% decreased appetite 8.4% NCT04017832 · Phase 3 · registry result, not featured evidence 3 mg nausea 10% diarrhoea 8.3% upper respiratory tract infection 7.2% NCT04017832 · Phase 3 · registry result, not featured evidence 14 mg decreased appetite 10.9% (placebo 0%) diarrhoea 9.3% (placebo 1.5%) upper respiratory tract infection 7% (placebo 4.6%) NCT04109547 · Phase 3 · registry result, not featured evidence 7 mg diarrhoea 9.2% (placebo 1.5%) upper respiratory tract infection 9.2% (placebo 4.6%) lipase increased 8.5% (placebo 0%) NCT04109547 · Phase 3 · registry result, not featured evidence 3 mg upper respiratory tract infection 8.5% (placebo 4.6%) lipase increased 5.4% (placebo 0%) nausea 4.6% (placebo 1.5%) NCT04109547 · Phase 3 · registry result, not featured evidence nausea 20.9% nasopharyngitis 10.3% headache 9.9% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 22.9% nasopharyngitis 13.4% diarrhoea 11.5% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 17% diarrhoea 10% nasopharyngitis 7% NCT02849080 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 18.8% (placebo 28.6%) constipation 12.5% (placebo 6.1%) decreased appetite 12.5% (placebo 0%) NCT03018028 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 16.3% (placebo 28.6%) constipation 12.2% (placebo 6.1%) nausea 10.2% (placebo 2%) NCT03018028 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 20.4% (placebo 28.6%) constipation 10.2% (placebo 6.1%) periarthritis 10.2% (placebo 4.1%) NCT03018028 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 30% constipation 15.4% nausea 9.2% NCT03015220 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 29.5% constipation 12.1% decreased appetite 9.1% NCT03015220 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 26% constipation 9.2% influenza 6.9% NCT03015220 · Phase 3 · registry result, not featured evidence 40 mg nausea 33.8% (placebo 1.4%) vomiting 19.7% (placebo 4.2%) decreased appetite 14.1% (placebo 1.4%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 35.7% (placebo 1.4%) vomiting 22.9% (placebo 4.2%) diarrhoea 17.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 32.9% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 15.7% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 20 mg nausea 35.7% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 17.1% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 10 mg nausea 33.3% (placebo 1.4%) diarrhoea 23.2% (placebo 9.9%) vomiting 20.3% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 5 mg nausea 14.3% (placebo 1.4%) headache 12.9% (placebo 5.6%) diarrhoea 10% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 2.5 mg nausea 12.9% (placebo 1.4%) nasopharyngitis 8.6% (placebo 12.7%) diarrhoea 7.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 40 weeks versus 26 weeks.
- ePopulation context differs: registered conditions differ.
- fAssessment timepoints differ: 72 weeks versus 104 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 7 more results
show 2 more results
show 7 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 4 more results
+ 1 further endpoint in the CSV export.
Semaglutide (Rybelsus)
show 11 more results
show 9 more results
show 36 more results
show 36 more results
show 49 more results
show 49 more results
show 10 more results
show 2 more results
show 11 more results
show 10 more results
show 10 more results
show 10 more results
+ 115 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Semaglutide (Rybelsus)'s landscape